Progesterone, 1% 1 ml 10 pcs

Progesterone is a gestagen. Hormone of the corpus luteum. Causes the uterine mucosa to transition from the proliferation phase caused by follicular hormone to the secretory phase and, after fertilization, promotes its transition to the state necessary for the development of the fertilized egg.

It reduces the excitability and contractility of the uterine muscles and fallopian tubes and stimulates the development of mammary gland terminal elements. It has no androgenic activity. Progesterone has a weak effect on protein metabolism, promotes fat deposition and glucose accumulation in the liver, and decreases sodium reabsorption in the renal tubules.

Progesterone has a blocking effect on the secretion of hypothalamic release factors LH and FSH, inhibits the formation of gonadotropic hormones in the pituitary gland and inhibits ovulation.

Pharmacokinetics

After injection, it is absorbed rapidly and almost completely. Metabolized in the liver, most metabolites form conjugates with glucuronic and sulfuric acids.

The T1/2 from plasma is a few minutes. It is excreted with the urine – 50-60% and with the feces – more than 10%. The amount of metabolites that are excreted in the urine varies depending on the phase of the corpus luteum.

Indications

Dysfunctional uterine bleeding, metrorrhagia, amenorrhea, recurrent miscarriage. Contraception.

Pharmacological effect

Progesterone is a gestagen. Corpus luteum hormone. Causes a transition of the uterine mucosa from the proliferation phase caused by follicular hormone to the secretory phase, and after fertilization contributes to its transition to the state necessary for the development of a fertilized egg.

Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes, stimulates the development of the end elements of the mammary gland. Does not have androgenic activity. Progesterone has a weak effect on protein metabolism, promotes the deposition of fats and the accumulation of glucose in the liver, and also reduces the reabsorption of sodium in the renal tubules.

Progesterone has a blocking effect on the secretion of hypothalamic release factors of LH and FSH, inhibits the formation of gonadotropic hormones in the pituitary gland and inhibits ovulation.

Pharmacokinetics

After intramuscular injection, it is absorbed quickly and almost completely. Metabolized in the liver, most metabolites form conjugates with glucuronic and sulfuric acids.

T1/2 from plasma is several minutes. Excreted in urine – 50-60% and in feces – more than 10%. The amount of metabolites that are excreted in the urine varies depending on the phase of the corpus luteum.

Active ingredient

Progesterone

Composition

Active ingredient:

progesterone

Contraindications

Severe liver or kidney dysfunction, hepatitis, thromboembolic diseases, vaginal bleeding of unknown origin, breast carcinoma (except for cases in which progesterone is used as part of combination therapy for this disease).

Side Effects

From the cardiovascular system: increased blood pressure.

Metabolism: edema.

From the digestive system: liver dysfunction, jaundice; rarely (with long-term use) – nausea, vomiting.

From the endocrine system: rarely (with long-term use) – decreased libido, weight gain, pain and tension in the mammary glands, irregular uterine bleeding.

From the side of the central nervous system: rarely (with long-term use) – headache, depression.

Interaction

Reduces the intensity of the action of drugs that stimulate the smooth muscles of the uterus, anabolic steroids, gonadotropic hormones of the anterior pituitary gland.

Reduces the lactogenic effect of oxytocin.

Enhances the effect of diuretics, antihypertensive drugs, immunosuppressants.

When used simultaneously with barbiturates, a decrease in the effect of progesterone is observed.

Storage conditions

In a place protected from light, in tightly closed packaging, at a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Dalkhimfarm, Russia